Want to see SLDB full AI Analyst Report?

Solid Biosciences (SLDB) Price & Analysis

1,601 Followers

SLDB Stock Chart & Stats

$9.89

-$0.15(-1.88%)

At close: Jul 24 4:00 PM EDT

$9.89

-$0.15(-1.88%)

Day’s Range― - ―

52-Week Range$3.79 - $11.45

Previous CloseN/A

Volume1.09M

Average Volume (3M)1.39M

Market Cap

$592.96M

Enterprise Value$1.08B

Total Cash (Recent Filing)$377.68M

Total Debt (Recent Filing)$20.16M

Price to Earnings (P/E)―

Beta1.87

Next Earnings

Nov 11, 2026

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.91

Shares Outstanding107,225,235

10 Day Avg. Volume1,462,475

30 Day Avg. Volume1,389,832

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)2.74

Price to Sales (P/S)0.00

P/FCF Ratio-3.13

Enterprise Value/Market Cap1.82

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.37K

Enterprise Value/Ebitda-5.24

Forecast

1Y Price Target

$20.00

Price Target Upside102.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-1.75

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageModest debt and low leverage provide greater financial flexibility than a heavily indebted balance sheet. This can reduce interest and refinancing pressure, allowing more of Solid’s available capital to support clinical development and other strategic priorities.

Focused Genetic-Medicine PipelineA focused genetic-medicine strategy gives Solid a clearly defined therapeutic area and concentrates resources on neuromuscular and cardiac opportunities. Progress in these programs could build specialized capabilities and support a durable position in targeted genetic therapies.

Equity Funding AccessThe expanded equity shelf gives Solid a documented mechanism to access capital for ongoing and planned initiatives. Although issuance may dilute shareholders, funding flexibility can extend development capacity and reduce dependence on immediate partnership or milestone proceeds.

Bears Say

No Commercial RevenueThe absence of recent revenue shows that Solid has not yet established a commercial earnings base. Without product sales or recurring operating revenue, financial progress remains tied to clinical and regulatory execution rather than internally generated business cash flow.

Widening LossesRapidly widening losses indicate that operating costs remain substantial without matching commercial revenue. Persistently negative profitability can consume capital needed for pipeline advancement and makes future financial performance highly sensitive to successful development milestones.

Heavy Cash BurnThe scale and deterioration of operating and free-cash-flow losses imply that Solid must continue funding development externally unless spending moderates or revenue emerges. Ongoing burn can shorten financial runway and constrain choices across clinical programs.

Solid Biosciences News

Solid Biosciences initiated with a Buy at UBS

UBS analyst Joon Lee initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $20 price target...

5d ago

SLDB

SLDB, APPS, RDW, BAC, SMG Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($SLDB) ), ( ($APPS) ), ( ($RDW) ), ( ($BAC)...

3d ago

BAC

RDW

Analyst Sees Accelerated Approval Upside for Solid Biosciences’ SGT-003 in Duchenne Muscular Dystrophy, Reiterates Buy Rating

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SLDB stock, giving a Buy rating yesterday....

4d ago

SLDB

Solid Biosciences: Buy Rating Reiterated With Unchanged $20 Price Target on Clinical and Regulatory Upside Potential

In a report released today, Daniel Clark from Leerink Partners reiterated a Buy rating on Solid Biosciences, with...

1M ago

SLDB

Solid Biosciences initiated with an Outperform at RBC Capital

RBC Capital analyst Luca Issi initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $18 price...

1M ago

SLDB

Solid Biosciences management to meet with Cantor

Meeting to be held in New York on September 15 hosted by Cantor. Published first on TheFly –...

1M ago

SLDB

Solid Biosciences price target raised to $26 from $16 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Solid Biosciences (SLDB) to $26 from $16 and keeps an...

2M ago

SLDB

Solid Biosciences assumed with a Buy at Truist

Truist analyst Danielle Brill assumed coverage of Solid Biosciences (SLDB) with a Buy rating with a price target...

2M ago

SLDB

Solid Biosciences: Buy Rating Reaffirmed on Advancing Duchenne and Friedreich’s Ataxia Programs, $25 Price Target Maintained

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Solid Biosciences,...

2M ago

SLDB

Solid Biosciences: Advancing Gene Therapy Pipeline, Strong Cash Runway Support Buy Rating with Unchanged $14 Price Target

Citi analyst Yigal Nochomovitz reiterated a Buy rating on Solid Biosciences on August 7 and set a price...

2M ago

SLDB

Solid Biosciences Updates Shelf for $200 Million Offering

Solid Biosciences ( ($SLDB) ) has shared an update. Solid Biosciences Inc. on August 6, 2026 filed a...

2M ago

SLDB

Solid Biosciences reports Q2 EPS (38c), consensus (47c)

Bo Cumbo, President and CEO of Solid Biosciences (SLDB), stated: “Our progress in the first half of 2026...

2M ago

SLDB

Solid Biosciences files automatic mixed securities shelf

17:01 EDT Solid Biosciences (SLDB) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

SLDB

Citizens biotech analysts hold an analyst/industry conference call

Biotech Analysts discuss Friedreich’s Ataxia developments from the patient community perspective (relevant companies LRMR SLDB BIIB PTCT LXEO...

4M ago

BIIB

DSGN

SLDB FAQ

What was Solid Biosciences’s price range in the past 12 months?

Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.

What is Solid Biosciences’s market cap?

Solid Biosciences’s market cap is $592.96M.

When is Solid Biosciences’s upcoming earnings report date?

Solid Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.

How were Solid Biosciences’s earnings last quarter?

Solid Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.082.

Is Solid Biosciences overvalued?

According to Wall Street analysts Solid Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Solid Biosciences pay dividends?

Solid Biosciences does not currently pay dividends.

What is Solid Biosciences’s EPS estimate?

Solid Biosciences’s EPS estimate is -0.41.

How many shares outstanding does Solid Biosciences have?

Solid Biosciences has 107,225,235 shares outstanding.

What happened to Solid Biosciences’s price movement after its last earnings report?

Solid Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -3.674%.

Which hedge fund is a major shareholder of Solid Biosciences?

Currently, no hedge funds are holding shares in SLDB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Solid Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-72.28%

Trailing 12-Months

Asset Growth

36.42%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Solid Biosciences

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Solid Biosciences (SLDB) Earnings & Revenues

Historic Earnings Reports

SLDB Stock 12 Month Forecast

Average Price Target

$20.00

▲(102.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","27":"$27","9.75":"$9.75","15.5":"$15.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.75,15.5,21.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,8.443076923076923,9.906153846153845,11.36923076923077,12.832307692307692,14.295384615384615,15.758461538461539,17.22153846153846,18.684615384615384,20.147692307692306,21.61076923076923,23.07384615384615,24.536923076923078,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.981538461538462,8.983076923076924,9.984615384615385,10.986153846153847,11.987692307692308,12.989230769230769,13.990769230769232,14.992307692307692,15.993846153846153,16.995384615384616,17.996923076923075,18.998461538461537,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.5200000000000005,8.06,8.6,9.14,9.68,10.219999999999999,10.76,11.3,11.84,12.379999999999999,12.92,13.459999999999999,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >